TP 252

Drug Profile

TP 252

Alternative Names: Eicosapentaenoic acid free fatty acid derivative - Thetis; EPA free fatty acid derivative - Thetis; EPA-FFA derivative - Thetis

Latest Information Update: 29 Jan 2016

Price : $50

At a glance

  • Originator Thetis Pharmaceuticals
  • Class Antineoplastics; Eicosanoids; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Familial adenomatous polyposis

Most Recent Events

  • 27 Jan 2016 Thetis Pharmaceuticals has patent protection for TP 252 in USA
  • 19 Jan 2016 TP 252 receives Orphan Drug status for Familial adenomatous polyposis in USA
  • 19 Jan 2016 Thetis Pharmaceuticals plans a phase I trial for Familial adenomatous polyposis (Adjunctive treatment)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top